通过向抑制Bcl-3增强B细胞恶性瘤中的细胞死亡
Renée Daams1, Thi Thu Phuong Tran1, Mohamed Jemaà1
1Department of Laboratory Medicine, Translational Cancer Research, Lund University, Medicon Village, Lund, Sweden.
Cell death & disease
|September 26, 2024
概括
一种新的Bcl-3抑制剂有效地减少了B细胞淋巴瘤和白血病细胞的增殖和诱导的亡. 这种向疗法在治疗缺乏临床进展的B细胞恶性瘤方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 这种t(14;19) 转位涉及B细胞淋巴增殖性恶性瘤中的Bcl-3基因,往往导致侵袭性疾病.
- Bcl-3蛋白调节NFκB信号传递,这是一种涉及各种癌症的途径.
- 目前针对瘤学中Bcl-3的治疗选择有限.
研究的目的:
- 研究B细胞淋巴瘤和白血病中Bcl-3抑制剂的治疗潜力.
- 阐明这些恶性瘤中Bcl-3抑制诱导的细胞死亡背后的机制.
主要方法:
- 用第二代Bcl-3抑制剂治疗B细胞淋巴瘤和白血病细胞系.
- 对细胞增殖,存活,线粒体膜潜力和细胞亡标记物的评估 (切割的caspase 3,cIAP1).
主要成果:
- 抑制Bcl-3显著降低了B细胞淋巴瘤和白血病细胞增殖和存活率.
- 抑制导致线粒体膜潜能和功能丧失.
- 增高的分裂酶3表达和减少的cIAP1表明了内在亡途径的激活.
结论:
- 抑制Bcl-3有效地通过内在途径诱导B细胞恶性瘤的亡.
- 这种Bcl-3抑制剂代表了B细胞淋巴瘤和白血病的潜在向治疗策略.
- 对Bcl-3抑制剂的进一步研究为癌症治疗开发提供了新的途径.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cytotoxic T Cells-mediated Immune Response
858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K


